Torigen Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Torigen Pharmaceuticals's estimated annual revenue is currently $9.5M per year.
- Torigen Pharmaceuticals's estimated revenue per employee is $155,000
Employee Data
- Torigen Pharmaceuticals has 61 Employees.
- Torigen Pharmaceuticals grew their employee count by 17% last year.
Torigen Pharmaceuticals's People
Name | Title | Email/Phone |
---|
Torigen Pharmaceuticals Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.2M | 1 | 0% | N/A | N/A |
#2 | $3.3M | 21 | -25% | N/A | N/A |
#3 | $9.8M | 81 | -10% | N/A | N/A |
#4 | $1.7M | 11 | 450% | N/A | N/A |
#5 | $20.3M | 131 | -23% | N/A | N/A |
#6 | $5.4M | 35 | -22% | N/A | N/A |
#7 | $2M | 13 | 44% | N/A | N/A |
#8 | $2.8M | 18 | 20% | N/A | N/A |
#9 | $0.3M | 4 | 0% | N/A | N/A |
#10 | $3.6M | 23 | -12% | N/A | N/A |
What Is Torigen Pharmaceuticals?
Torigen Pharmaceuticals is focused on veterinary cancer care. Our product, VetiVax, is a revolutionary cancer immunotherapy that uses the patient's own tumor cells to create a personalized treatment which educates the immune system to recognize the tumor as foreign. With over 12 years of supporting research, VetiVax allows for a variety of tumor antigens to be presented to the immune system. This abundant choice increases the likelihood of a successful response.
keywords:N/AN/A
Total Funding
61
Number of Employees
$9.5M
Revenue (est)
17%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Torigen Pharmaceuticals News
2022-03-30 - The Worldwide Animal Vaccines Industry is Expected to ...
Brilliant Bio Pharma Private limited 12.5. Ceva Sante Animale ... Torigen Pharmaceuticals Inc. 12.18. Vaxxinova GmbH
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $18.1M | 61 | 11% | N/A |
#2 | $11.5M | 61 | 0% | N/A |
#3 | $13.9M | 63 | 2% | N/A |
#4 | $15.6M | 64 | 8% | N/A |
#5 | $15.8M | 65 | -14% | N/A |